Phase 1
Phase 2
Phase 3
Clinical
Company A
DNA vaccine
315 cases supported
Company B
mRNA vaccine
180 cases supported
Company C
mRNA vaccine
180 cases supported
Company D
Synthetic antigen vaccine
486 cases supported
Company E
Virus vector vaccine
2000 cases supported
Company F
DNA vaccine
822cases supported
Company G
Synthetic antigen vaccine
12,740 cases supported
Non-clinical
Company A
DNA vaccine
20 cases supported
Company B
DNA vaccine
12 cases supported
Company D
mRNA vaccine
3 cases supported
Company F
mRNA vaccine
39 cases supported
Company H
Synthetic antigen vaccine
181 cases supported
Company J
DNA vaccine
will be supported
Company C
mRNA vaccine
Company E
mRNA vaccine
Company G
mRNA vaccine
Company I
mRNA vaccine
